Pfizer is betting on next-gen cancer drugs to offset slowing demand for COVID vaccines

Pfizer expects cancer drugs developed by Seagen, the biotech company it acquired last year, to generate $10 billion in sales by 2030

By Bruce Gil, Quartz

Pfizer (PFE) is betting that next-gen cancer therapies will be a key part of its business as demand for COVID vaccines continue to dwindle.

More here >

This post was originally published on this site

Marketing block

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Sign Up for Updates

Get the latest stock market news from Phil by signing up for our newsletter!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Pfizer is betting on next-gen cancer drugs to offset slowing demand for COVID vaccines